S&P 500   3,368.02 (+0.22%)
DOW   28,025.18 (+0.84%)
QQQ   269.43 (-0.33%)
AAPL   446.05 (-1.08%)
MSFT   207.00 (-0.60%)
FB   264.07 (+0.41%)
GOOGL   1,498.42 (+0.11%)
AMZN   3,121.43 (-0.85%)
NVDA   440.82 (-1.29%)
CGC   17.50 (-2.40%)
BABA   250.14 (+0.81%)
TSLA   1,391.89 (-1.88%)
GE   6.82 (+2.25%)
MU   48.83 (-0.65%)
AMD   78.62 (-4.40%)
T   30.47 (+0.89%)
F   7.34 (+3.53%)
ACB   10.08 (-1.37%)
GILD   68.33 (-0.26%)
NFLX   472.44 (-2.26%)
DIS   131.82 (+2.35%)
BAC   27.46 (+3.35%)
BA   186.57 (+3.99%)
S&P 500   3,368.02 (+0.22%)
DOW   28,025.18 (+0.84%)
QQQ   269.43 (-0.33%)
AAPL   446.05 (-1.08%)
MSFT   207.00 (-0.60%)
FB   264.07 (+0.41%)
GOOGL   1,498.42 (+0.11%)
AMZN   3,121.43 (-0.85%)
NVDA   440.82 (-1.29%)
CGC   17.50 (-2.40%)
BABA   250.14 (+0.81%)
TSLA   1,391.89 (-1.88%)
GE   6.82 (+2.25%)
MU   48.83 (-0.65%)
AMD   78.62 (-4.40%)
T   30.47 (+0.89%)
F   7.34 (+3.53%)
ACB   10.08 (-1.37%)
GILD   68.33 (-0.26%)
NFLX   472.44 (-2.26%)
DIS   131.82 (+2.35%)
BAC   27.46 (+3.35%)
BA   186.57 (+3.99%)
S&P 500   3,368.02 (+0.22%)
DOW   28,025.18 (+0.84%)
QQQ   269.43 (-0.33%)
AAPL   446.05 (-1.08%)
MSFT   207.00 (-0.60%)
FB   264.07 (+0.41%)
GOOGL   1,498.42 (+0.11%)
AMZN   3,121.43 (-0.85%)
NVDA   440.82 (-1.29%)
CGC   17.50 (-2.40%)
BABA   250.14 (+0.81%)
TSLA   1,391.89 (-1.88%)
GE   6.82 (+2.25%)
MU   48.83 (-0.65%)
AMD   78.62 (-4.40%)
T   30.47 (+0.89%)
F   7.34 (+3.53%)
ACB   10.08 (-1.37%)
GILD   68.33 (-0.26%)
NFLX   472.44 (-2.26%)
DIS   131.82 (+2.35%)
BAC   27.46 (+3.35%)
BA   186.57 (+3.99%)
S&P 500   3,368.02 (+0.22%)
DOW   28,025.18 (+0.84%)
QQQ   269.43 (-0.33%)
AAPL   446.05 (-1.08%)
MSFT   207.00 (-0.60%)
FB   264.07 (+0.41%)
GOOGL   1,498.42 (+0.11%)
AMZN   3,121.43 (-0.85%)
NVDA   440.82 (-1.29%)
CGC   17.50 (-2.40%)
BABA   250.14 (+0.81%)
TSLA   1,391.89 (-1.88%)
GE   6.82 (+2.25%)
MU   48.83 (-0.65%)
AMD   78.62 (-4.40%)
T   30.47 (+0.89%)
F   7.34 (+3.53%)
ACB   10.08 (-1.37%)
GILD   68.33 (-0.26%)
NFLX   472.44 (-2.26%)
DIS   131.82 (+2.35%)
BAC   27.46 (+3.35%)
BA   186.57 (+3.99%)
Log in

NASDAQ:BLUEbluebird bio Stock Price, Forecast & News

$63.76
-2.01 (-3.06 %)
(As of 08/11/2020 02:31 PM ET)
Add
Compare
Today's Range
$63.27
Now: $63.76
$65.78
50-Day Range
$59.50
MA: $63.24
$67.55
52-Week Range
$38.95
Now: $63.76
$124.15
Volume11,479 shs
Average Volume731,107 shs
Market Capitalization$4.22 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.32
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; and TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Read More
bluebird bio logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLUE
CUSIPN/A
Phone339-499-9300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$44.67 million
Book Value$23.22 per share

Profitability

Net Income$-789,610,000.00
Net Margins-272.66%

Miscellaneous

Employees1,090
Market Cap$4.22 billion
Next Earnings Date10/29/2020 (Estimated)
OptionableOptionable
$63.76
-2.01 (-3.06 %)
(As of 08/11/2020 02:31 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

How has bluebird bio's stock price been impacted by Coronavirus (COVID-19)?

bluebird bio's stock was trading at $61.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BLUE shares have increased by 3.7% and is now trading at $63.76.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of bluebird bio?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for bluebird bio
.

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for bluebird bio
.

How were bluebird bio's earnings last quarter?

bluebird bio Inc (NASDAQ:BLUE) released its earnings results on Wednesday, August, 5th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($2.58) by $2.22. bluebird bio had a negative return on equity of 47.02% and a negative net margin of 272.66%.
View bluebird bio's earnings history
.

What price target have analysts set for BLUE?

18 analysts have issued 12-month price objectives for bluebird bio's stock. Their forecasts range from $68.00 to $160.00. On average, they expect bluebird bio's stock price to reach $103.77 in the next twelve months. This suggests a possible upside of 62.7% from the stock's current price.
View analysts' price targets for bluebird bio
.

Has bluebird bio been receiving favorable news coverage?

News stories about BLUE stock have trended neutral recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. bluebird bio earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about bluebird bio
.

Who are some of bluebird bio's key competitors?

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include BioMarin Pharmaceutical (BMRN), Opko Health (OPK), NVIDIA (NVDA), Puma Biotechnology (PBYI), Celgene (CELG), Gilead Sciences (GILD), Incyte (INCY), Alibaba Group (BABA), Micron Technology (MU) and Medivation (MDVN).

Who are bluebird bio's key executives?

bluebird bio's management team includes the following people:
  • Mr. Nick Leschly, Pres, CEO & Director (Age 46)
  • Mr. Jason F. Cole, Chief Operating & Legal Officer and Sec. (Age 46)
  • Dr. Philip D. Gregory, Chief Scientific Officer (Age 48)
  • Mr. Jeffrey T. Walsh, Chief Strategy Officer (Age 53)
  • Dr. David M. Davidson, Chief Medical Officer (Age 55)

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Victory Capital Management Inc. (2.75%), First Trust Advisors LP (2.10%), TimesSquare Capital Management LLC (1.68%), Platinum Investment Management Ltd. (0.91%), Frontier Capital Management Co. LLC (0.81%) and Candriam Luxembourg S.C.A. (0.75%). Company insiders that own bluebird bio stock include Alison Cecily Finger, David Davidson, James Mandell, Jason Cole, Jeffrey T Walsh, Joanne Smith-Farrell, Kory James Wentworth, Nick Leschly, Philip D Gregory, Susanna Gatti High and William D Baird III.
View institutional ownership trends for bluebird bio
.

Which major investors are selling bluebird bio stock?

BLUE stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Peregrine Capital Management LLC, GAM Holding AG, SG Americas Securities LLC, Trexquant Investment LP, Amalgamated Bank, US Bancorp DE, and Rothschild Investment Corp IL. Company insiders that have sold bluebird bio company stock in the last year include Alison Cecily Finger, David Davidson, Jeffrey T Walsh, Joanne Smith-Farrell, Kory James Wentworth, Nick Leschly, Philip D Gregory, and William D Baird III.
View insider buying and selling activity for bluebird bio
.

Which major investors are buying bluebird bio stock?

BLUE stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Frontier Capital Management Co. LLC, Anchor Capital Advisors LLC, Candriam Luxembourg S.C.A., TimesSquare Capital Management LLC, Russell Investments Group Ltd., Great Lakes Advisors LLC, and Principal Financial Group Inc..
View insider buying and selling activity for bluebird bio
.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $63.76.

How big of a company is bluebird bio?

bluebird bio has a market capitalization of $4.22 billion and generates $44.67 million in revenue each year. The biotechnology company earns $-789,610,000.00 in net income (profit) each year or ($14.31) on an earnings per share basis. bluebird bio employs 1,090 workers across the globe.

What is bluebird bio's official website?

The official website for bluebird bio is www.bluebirdbio.com.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.